nach oben

Erschienen in:

01.05.2021 | Review Article

The role of interleukins and the widely studied TNF-α in non-Hodgkin’s lymphoma

verfasst von: Kyle P. D’mello, Lei Zhao, Erin C. Kaser, Ziwen Zhu, Huaping Xiao, Mark R. Wakefield, Qian Bai, Yujiang Fang

Erschienen in: Medical Oncology | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

Non-Hodgkin’s lymphoma is a relatively common cancer with malignant tendencies. Although there is no current cure for the disease, research has been successful in figuring out the mechanisms of how the disease progresses, however, there is still a lot of unknowns, and more research must be done to find the ultimate cause of the disease. Interleukins and various cytokines play unique roles in the development of cancer. This review article summarizes the pathophysiology between certain interleukins and non-Hodgkin’s lymphoma. Although TNF-α is not an interleukin, the article examines TNF-α due to its high correspondence with cancer. The article also describes a promising immunotherapy for the disease, while looking at immunotherapies that have been successful in other types of cancer and disease.

Elmslie RE, Dow SW, Ogilvie GK. Interleukins: biological properties and therapeutic potential. J Vet Intern Med. 1991;5(5):283–93. https://doi.org/10.1111/j.1939-1676.1991.tb03135.x.CrossRefPubMed

Davis MR, Zhu Z, Hansen DM, Bai Q, Fang Y. The role of IL-21 in immunity and cancer. Cancer Lett. 2015;358(2):107–14. https://doi.org/10.1016/j.canlet.2014.12.047.CrossRefPubMed

Vaillant AAJ, Qurie A. Interleukin. StatPearls [Internet]. 2019.

Ding VA, Zhu Z, Xiao H, Wakefield MR, Bai Q, Fang Y. The role of IL-37 in cancer. Med Oncol. 2016;33(7):68. https://doi.org/10.1007/s12032-016-0782-4.CrossRefPubMed

Xu DH, Zhu Z, Wakefield MR, Xiao H, Bai Q, Fang Y. The role of IL-11 in immunity and cancer. Cancer Lett. 2016;373(2):156–63. https://doi.org/10.1016/j.canlet.2016.01.004.CrossRefPubMed

Catalan-Dibene J, McIntyre LL, Zlotnik A. Interleukin 30 to interleukin 40. J Interferon Cytokine Res. 2018;38(10):423–39. https://doi.org/10.1089/jir.2018.0089.CrossRefPubMedPubMedCentral

Kelm NE, Zhu Z, Ding VA, Xiao H, Wakefield MR, Bai Q, et al. The role of IL-29 in immunity and cancer. Crit Rev Oncol Hematol. 2016;106:91–8. https://doi.org/10.1016/j.critrevonc.2016.08.002.CrossRefPubMedPubMedCentral

Lee JE, Zhu Z, Bai Q, Brady TJ, Xiao H, Wakefield MR, et al. The role of interleukin-9 in cancer. Pathol Oncol Res. 2020;26(4):2017–22. https://doi.org/10.1007/s12253-019-00665-6.CrossRefPubMed

Lin J, Zhu Z, Xiao H, Wakefield MR, Ding VA, Bai Q, et al. The role of IL-7 in immunity and cancer. Anticancer Res. 2017;37(3):963–7. https://doi.org/10.21873/anticanres.11405.CrossRefPubMed

10.

Setrerrahmane S, Xu H. Tumor-related interleukins: old validated targets for new anti-cancer drug development. Mol Cancer. 2017;16(1):153. https://doi.org/10.1186/s12943-017-0721-9.CrossRefPubMedPubMedCentral

11.

Yoshimoto T, Morishima N, Okumura M, Chiba Y, Xu M, Mizuguchi J. Interleukins and cancer immunotherapy. Immunotherapy. 2009;1(5):825–44. https://doi.org/10.2217/imt.09.46.CrossRefPubMed

12.

Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011;105(11):1684–92. https://doi.org/10.1038/bjc.2011.450.CrossRefPubMedPubMedCentral

13.

Buhtoiarov IN. Pediatric lymphoma. Pediatr Rev. 2017;38(9):410–23. https://doi.org/10.1542/pir.2016-0152.CrossRefPubMed

14.

Sandlund JT, Martin MG. Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum. Hematology Am Soc Hematol Educ Program. 2016;2016(1):589–97. https://doi.org/10.1182/asheducation-2016.1.589.CrossRefPubMedPubMedCentral

15.

Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet. 2017;390(10091):298–310. https://doi.org/10.1016/S0140-6736(16)32407-2.CrossRefPubMed

16.

Ansell SM, editor. Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clinic Proceedings; Elsevier:2015.

17.

Jiang T, Zhou C, Ren S. Role of IL-2 in cancer immunotherapy. Oncoimmunology. 2016;5(6):e1163462. https://doi.org/10.1080/2162402X.2016.1163462.CrossRefPubMedPubMedCentral

18.

Song H, Chen L, Cha Z, Bai J. Interleukin 2 gene polymorphisms are associated with non-Hodgkin lymphoma. DNA Cell Biol. 2012;31(7):1279–84. https://doi.org/10.1089/dna.2011.1603.CrossRefPubMedPubMedCentral

19.

Whiteside TL. Measurement of cytotoxic activity of NK/LAK cells. Curr Protoc Immunol. 2000;35(1):7–18.

20.

Kelly-Welch AE, Hanson EM, Boothby MR, Keegan AD. Interleukin-4 and interleukin-13 signaling connections maps. Science. 2003;300(5625):1527–8. https://doi.org/10.1126/science.1085458.CrossRefPubMed

21.

Soydinc HO, Guney N, Basaran M, Duranyildiz D, Yasasever V. Clinical significance of interleukin-4 and interleukin-18 levels in aggressive non-Hodgkin’s lymphoma patients. Genet Mol Res. 2016. https://doi.org/10.4238/gmr.15038590.CrossRefPubMed

22.

Baggiolini M, Clark-Lewis I. Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett. 1992;307(1):97–101. https://doi.org/10.1016/0014-5793(92)80909-z.CrossRefPubMed

23.

Lee HL, Eom HS, Yun T, Kim HJ, Park WS, Nam BH, et al. Serum and urine levels of interleukin-8 in patients with non-Hodgkin’s lymphoma. Cytokine. 2008;43(1):71–5. https://doi.org/10.1016/j.cyto.2008.04.004.CrossRefPubMed

24.

Luciani MG, Stoppacciaro A, Peri G, Mantovani A, Ruco LP. The monocyte chemotactic protein a (MCP-1) and interleukin 8 (IL-8) in Hodgkin’s disease and in solid tumours. Mol Pathol. 1998;51(5):273–6. https://doi.org/10.1136/mp.51.5.273.CrossRefPubMedPubMedCentral

25.

Russo RC, Garcia CC, Teixeira MM, Amaral FA. The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases. Expert Rev Clin Immunol. 2014;10(5):593–619. https://doi.org/10.1586/1744666X.2014.894886.CrossRefPubMed

26.

Mannino MH, Zhu Z, Xiao H, Bai Q, Wakefield MR, Fang Y. The paradoxical role of IL-10 in immunity and cancer. Cancer Lett. 2015;367(2):103–7. https://doi.org/10.1016/j.canlet.2015.07.009.CrossRefPubMed

27.

Cortes J, Kurzrock R. Interleukin-10 in non-Hodgkin’s lymphoma. Leuk Lymphoma. 1997;26(3–4):251–9. https://doi.org/10.3109/10428199709051774.CrossRefPubMed

28.

Li G, Li D. Relationship between IL-10 gene polymorphisms and the risk of non-Hodgkin lymphoma: a meta-analysis. Hum Immunol. 2016;77(5):418–25.CrossRef

29.

Yasuda K, Nakanishi K, Tsutsui H. Interleukin-18 in health and disease. Int J Mol Sci. 2019;20(3):649. https://doi.org/10.3390/ijms20030649.CrossRefPubMedCentral

30.

Rothman N, Skibola CF, Wang SS, Morgan G, Lan Q, Smith MT, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol. 2006;7(1):27–38. https://doi.org/10.1016/S1470-2045(05)70434-4.CrossRefPubMed

31.

Patel P, Walborn A, Rondina M, Fareed J, Hoppensteadt D. Markers of inflammation and infection in sepsis and disseminated intravascular coagulation. Clin Appl Thromb Hemost. 2019;25:1076029619843338. https://doi.org/10.1177/1076029619843338.CrossRefPubMedPubMedCentral

32.

Xu DH, Zhu Z, Xiao H, Wakefield MR, Bai Q, Nicholl MB, et al. Unveil the mysterious mask of cytokine-based immunotherapy for melanoma. Cancer Lett. 2017;394:43–51. https://doi.org/10.1016/j.canlet.2017.02.022.CrossRefPubMed

33.

Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192(12):5451–8. https://doi.org/10.4049/jimmunol.1490019.CrossRefPubMedPubMedCentral

34.

Farhood B, Najafi M, Mortezaee K. CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol. 2019;234(6):8509–21. https://doi.org/10.1002/jcp.27782.CrossRefPubMed

35.

Guo Y, Luan L, Patil NK, Sherwood ER. Immunobiology of the IL-15/IL-15Rα complex as an antitumor and antiviral agent. Cytokine Growth Factor Rev. 2017;38:10–21.CrossRef

36.

Waldmann TA. Interleukin-15 in the treatment of cancer. Expert Rev Clin Immunol. 2014;10(12):1689–701. https://doi.org/10.1586/1744666X.2014.973856.CrossRefPubMedPubMedCentral

37.

Patidar M, Yadav N, Dalai SK. Interleukin 15: a key cytokine for immunotherapy. Cytokine Growth Factor Rev. 2016;31:49–59. https://doi.org/10.1016/j.cytogfr.2016.06.001.CrossRefPubMed

38.

Zheng Y, Yu K, Du J, Jiang L, Zhang S, Han Y, et al. Potential therapeutic strategy for non-Hodgkin lymphoma by anti-CD20scFvFc/CD28/CD3zeta gene tranfected T cells. J Exp Clin Cancer Res. 2010;29(1):121. https://doi.org/10.1186/1756-9966-29-121.CrossRefPubMedPubMedCentral

39.

Carter AJ, Nguyen CN. A comparison of cancer burden and research spending reveals discrepancies in the distribution of research funding. BMC Public Health. 2012;12(1):526. https://doi.org/10.1186/1471-2458-12-526.CrossRefPubMedPubMedCentral

Titel: The role of interleukins and the widely studied TNF-α in non-Hodgkin’s lymphoma
verfasst von: Kyle P. D’mello
Lei Zhao
Erin C. Kaser
Ziwen Zhu
Huaping Xiao
Mark R. Wakefield
Qian Bai
Yujiang Fang
Publikationsdatum: 01.05.2021
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 5/2021
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-021-01504-y

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

The role of interleukins and the widely studied TNF-α in non-Hodgkin’s lymphoma

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2021

Diosmetin induces apoptosis in ovarian cancer cells by activating reactive oxygen species and inhibiting the Nrf2 pathway

OLIGO-AIRO: a national survey on the role of radiation oncologist in the management of OLIGO-metastatic patients on the behalf of AIRO

The role of various interleukins in acute myeloid leukemia

Melittin, a honeybee venom derived peptide for the treatment of chemotherapy-induced peripheral neuropathy

Can artificial intelligence overtake human intelligence on the bumpy road towards glioma therapy?

SNRPB is a mediator for cellular response to cisplatin in non-small-cell lung cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie